Kryptoscan (Krypton (81mkr))

After inhalation, Krypton-81m distributes evenly in the alveolar air spaces. Its short‑lived decay emits gamma photons that are captured by a gamma camera, creating a visual map of air distribution within the lungs, which reflects functional ventilation.

The administered activity of Kryptoscan is determined by the prescribing nuclear medicine physician based on the specific imaging protocol, patient size, and equipment. Dosing is individualized and not standardized across all patients.

Kryptoscan is generally avoided in pregnant or breastfeeding individuals because the radioactive gas can expose the fetus or infant to ionizing radiation. Use is only considered when the diagnostic benefit outweighs the potential risk and after specialist consultation.

To request Kryptoscan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Krypton-81m offers rapid decay and high‑resolution imaging compared with longer‑lived gases such as Xenon‑133. Its short half‑life reduces radiation exposure, but it requires on‑site generator capability, whereas alternatives may be supplied in larger containers with longer shelf‑life.

Kryptoscan should be stored at ambient temperature, protected from excessive heat and direct sunlight, and kept in its original sealed cylinder. Handling must follow radiation safety guidelines, including use of shielding, proper labeling, and routine leak testing.

Kryptoscan is administered by inhalation through a calibrated delivery system. The patient breathes the gas for a short period while the gamma camera acquires images. Administration is performed by trained nuclear medicine staff in a controlled environment.

The primary serious risks include radiation‑induced tissue injury and rare allergic reactions that may lead to bronchospasm or anaphylaxis. Proper patient screening and adherence to radiation protection protocols minimize these risks.

Kryptoscan should not be used in patients with known hypersensitivity to the gas, in pregnant or breastfeeding women unless absolutely necessary, and in individuals with severe uncontrolled respiratory disease where inhalation could exacerbate symptoms.